Zhejiang Hisun Pharmaceutical Co. Ltd. in collaboration with Medspace, Inc., is conducting a trial of AD-35’s effectiveness for Mild to Moderate Alzheimer’s since October 4, 2018 and will continue till July 31, 2020.
This trial will test the safety, tolerability, and effects of AD-35 on cognitive function in older adults with mild to moderate Alzheimer’s disease.
AD-35 is small-molecule compound being investigated for the treatment and prevention of Alzheimer’s disease. Earlier research shows the compound may inhibit aggregation of amyloid-beta, a protein that accumulates abnormally in Alzheimer’s disease.
Find out whether you or your loved one is eligible for the trial: https://www.nia.nih.gov/alzheimers/clinical-trials/ad-35-mild-moderate-alzheimers